Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 14/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 11/20 | 0.55 |
| ▸ | BCR | P11274 | 10/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.55 |
| ▸ | PRKCA | P17252 | 2/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | KIT | P10721 | 7/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24251137 | 0.96 | ABL1 (0.54) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL24251119 | 0.95 | ABL1 (0.56) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL29551437 | 0.92 | ABL1 (0.58) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL24250888 | 0.92 | ABL1 (0.58) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL29551056 | 0.91 | ABL1 (0.65) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL24251076 | 0.91 | ABL1 (0.65) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL29551191 | 0.89 | ABL1 (0.57) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL24250892 | 0.89 | ABL1 (0.57) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL24250952 | 0.88 | ABL1 (0.60) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL29551410 | 0.88 | ABL1 (0.60) | ABL1PDGFRABCRPDGFRBPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114127065-A | Compounds for the treatment of neurodegenerative diseases and cancer | 鸿仪有限责任公司 | 2022-03-01 | — | — | CN | claimed |
| US-20220048893-A1 | Compounds for Treating Neurodegenerative Diseases and Cancers | HONGYI & ASS LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-20220048893-A1 | Compounds for Treating Neurodegenerative Diseases and Cancers | HONGYI & ASS LLC (US) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048893-A1 | Compounds for Treating Neurodegenerative Diseases and Cancers | SNCA, NGF, SLC18A2 | ABL1 695/4885PDGFRA 145/4885BCR 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.